1/3 Many thanks @jaketapper for hosting me @TheLeadCNN re: revised CDC guidelines. I indicated that I don’t have a specific problem with them, but they are not properly contextualized and placed in the context of a roadmap or continuum.
2/3 the way to do that is articulate what nation looks like by summer if approach full vaccination, meaning 20% of country under the age of 12 and ineligible because of age, and 80% adults/adolescents. The. transmission declines dramatically, we get back to 2019 style life
3/3 by summer life may get close to normal for many Americans. Between then and now the CDC should lay out a road map of gradually loosening restrictions as transmission declines. Right now at 50K new cases per day we’re at Summer 2020 levels, this decreases as we vaccinate >60%
We also discussed on the @TheLeadCNN@TheLeadCNN lead the urgency to confront Russian antivaccine antiscience aggression and local antivaccine groups in US and now conservative groups described in my @nature essay today nature.com/articles/d4158…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1/5 Many thanks @JohnBerman @drsanjaygupta for hosting me on @AC360 tonight discussing the 3 major sources of antivaccine disinformation in US:
2/5: well funded and organized antivaccine groups, with 58 million followers according to the @CCDHate
3/5: the conservative lobby that began as Republican Tea Party PACs in South Central US TX OK now becoming mainstream in the GOP as evidenced by nighttime anchors on conservative cable networks defiant of vaccines and masks
1/4 Many thanks @morningmika @JoeNBC @Morning_Joe for hosting me to discuss the urgency of helping India produce vaccines for itself and the fact that we’re relying on India to produce vaccines for Africa, Asia, Latin America
2/4 Right now we depend on Serum Institute in Pune to produce AZOx vaccine, Biological E to produce J&J vaccine and our recombinant protein vaccine, Bharat an inactivated virus vaccine, and now Sputnik V is being produced in India
3/4 Therefore yesterday’s US announcement of releasing export restrictions to India is welcome, as well support for BioE. We need US Government to reassert global leadership in vaccine diplomacy
Deeply appreciate @nytimes @nytopinion Editors for your enthusiastic support of our low cost ($1.50) COVID19 “people’s vaccine” now going into phase 3 trials, and being scaled to 1 billion doses. We need support for another 4-5 billion. nytimes.com/2021/04/24/opi…
Many thanks @SRuhle @RuhleOnMSNBC for hosting me on what we must do to halt virus transmission in America: we’re still only at 40% of the US population with a single dose, and given high transmissibility of B.1.1.7 UK and B.1.429 CA, that number must double
Unfortunately we won’t get there unless we can persuade the Conservative 1/3 of the nation to vaccinate. But 4 news polls: Kaiser, Texas A&M, Monmouth Univ, PBS NewsHour all point to “White Republicans” as the most vaccine refusing group.
And it doesn’t help that now the Nighttime Fox News anchors go on antivaccine rants and target scientists. This is self defeating and will delay our time when we can go without masks.
A reason, when virus transmission is still high and especially with B.1.1.7 variant, I typically wear a mask in public or when with others. As we head towards greater vaccine coverage in US about 75% by June, transmission will slow and masks less essential cnn.com/2021/04/14/hea…
The way I see this unfolding: as we advance towards high vaccine coverage of adults and adolescents by summer virus transmission will finally decrease substantially and then vaccinated individuals can feel much safer without masks. But we’ll still need to be mindful...
We should be prepared for the possible seasonality of COVID19 so that in January 2022 we might need to re-mask for a period of a few weeks if transmission goes back up. It requires our situational awareness and following CDC public health recommendations and guidance
Many thanks @chucktodd for hosting me on @MeetThePress with @ellisonbarber discussing how we navigate issues around JnJ vaccine and urgency to vaccinate ahead of an accelerating B.1.1.7 variant
Presumably the pause is to compare notes with European and UK regulators for both adenovirus vectored vaccines AZOx and JnJ. I said possible outcome would be if we could identify a specific at risk population say premenopausal women with a second risk factor such as BC, smoking
Then in this case we could redirect JnJ away from this group. I also stated more philosophically that this is a predictable consequence of only focusing on innovative vaccine technologies. We made some great vaccines but introduced some unnecessary risks and as a consequence..